MX2016009052A - Derivados heterociclicos biciclicos como inhibidores de bromodominio. - Google Patents

Derivados heterociclicos biciclicos como inhibidores de bromodominio.

Info

Publication number
MX2016009052A
MX2016009052A MX2016009052A MX2016009052A MX2016009052A MX 2016009052 A MX2016009052 A MX 2016009052A MX 2016009052 A MX2016009052 A MX 2016009052A MX 2016009052 A MX2016009052 A MX 2016009052A MX 2016009052 A MX2016009052 A MX 2016009052A
Authority
MX
Mexico
Prior art keywords
bicyclic heterocyclic
heterocyclic derivatives
bromodomain inhibitors
pharmaceutically acceptable
diseases
Prior art date
Application number
MX2016009052A
Other languages
English (en)
Inventor
Sasmal Sanjita
Samajdar Susanta
Abbineni Chandrasekhar
Hosahalli Subramanya
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2016009052A publication Critical patent/MX2016009052A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención proporciona derivados heterocíclicos bicíclicos de la fórmula (I), que pueden ser terapéuticamente útiles, más particularmente como inhibidores de bromodominio; (ver Fórmula) en la cual R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n y la línea punteada tienen el mismo significado dado en la especificación, y sales farmacéuticamente aceptables o eestereoisómeros farmacéuticamente aceptables de los mismos que son útiles en el tratamiento y prevención de enfermedades o trastornos, en particular su uso en enfermedades o trastornos asociados como inhibidores de bromodominio. La presente invención también proporciona la preparación de los compuestos y formulaciones farmacéuticas que comprenden al menos uno de los derivados heterocíclicos bicíclicos de la fórmula (I), junto con un portador, diluyente o excipiente farmacéuticamente aceptable de los mismos.
MX2016009052A 2014-01-09 2015-01-06 Derivados heterociclicos biciclicos como inhibidores de bromodominio. MX2016009052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN125CH2014 2014-01-09
PCT/IB2015/050090 WO2015104653A1 (en) 2014-01-09 2015-01-06 Bicyclic heterocyclic derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
MX2016009052A true MX2016009052A (es) 2016-09-09

Family

ID=52462967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009052A MX2016009052A (es) 2014-01-09 2015-01-06 Derivados heterociclicos biciclicos como inhibidores de bromodominio.

Country Status (30)

Country Link
US (2) US10077259B2 (es)
EP (1) EP3092227B1 (es)
JP (1) JP6480944B2 (es)
KR (1) KR102394518B1 (es)
CN (1) CN106061966B (es)
AU (1) AU2015205339B2 (es)
BR (1) BR112016015311B1 (es)
CA (1) CA2934788C (es)
CL (1) CL2016001737A1 (es)
CY (1) CY1122046T1 (es)
DK (1) DK3092227T3 (es)
EA (1) EA029224B1 (es)
ES (1) ES2687497T3 (es)
HR (1) HRP20181650T1 (es)
HU (1) HUE041546T2 (es)
IL (1) IL246140B (es)
LT (1) LT3092227T (es)
MA (1) MA39172B1 (es)
MX (1) MX2016009052A (es)
MY (1) MY190835A (es)
PE (1) PE20161021A1 (es)
PH (1) PH12016501355A1 (es)
PL (1) PL3092227T3 (es)
PT (1) PT3092227T (es)
RS (1) RS57586B1 (es)
SA (1) SA516371448B1 (es)
SG (1) SG11201604916YA (es)
SI (1) SI3092227T1 (es)
UA (1) UA117165C2 (es)
WO (1) WO2015104653A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3581576B1 (en) 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CA2946731C (en) 2014-04-23 2022-06-07 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
CN107810185A (zh) * 2015-07-02 2018-03-16 奥赖恩公司 作为溴结构域抑制剂的二环杂环衍生物
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
AU2016305513A1 (en) 2015-08-11 2018-03-08 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
IL257340B2 (en) 2015-08-12 2023-10-01 Neomed Inst Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN105198871A (zh) * 2015-11-06 2015-12-30 中国药科大学 一类喹喔啉酮类化合物及其制备方法和用途
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
WO2017184462A1 (en) * 2016-04-18 2017-10-26 Celgene Quanticel Research, Inc. Therapeutic compounds
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
JP2020503312A (ja) 2016-12-22 2020-01-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換１，２，４−チアジアゾリルピロロンおよび１，２，４−チアジアゾリルヒダントイン、ならびにその塩、ならびにその除草剤としての使用
CN110392680A (zh) 2016-12-22 2019-10-29 拜耳作物科学股份公司 取代的唑基吡咯酮和唑基乙内酰脲及其盐及其作为除草活性物质的用途
WO2018161876A1 (zh) * 2017-03-08 2018-09-13 中国科学院上海药物研究所 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
CN110092782B (zh) * 2018-01-30 2022-10-21 中国科学院广州生物医药与健康研究院 一种苯并六元氮杂环化合物及其制备方法和应用
CN110960528A (zh) * 2018-09-30 2020-04-07 四川大学 Ar和bet双重抑制剂及其用途
US11192900B2 (en) 2018-10-30 2021-12-07 Nuvation Bio Inc. Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
US20220204493A1 (en) 2019-04-11 2022-06-30 Orion Corporation Crystalline form of a bet-inhibitor and manufacture thereof
WO2021003310A1 (en) 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102600176B1 (ko) * 2021-10-18 2023-11-10 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
CA2580811C (en) * 2004-09-28 2014-04-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
US9447069B2 (en) * 2012-04-30 2016-09-20 Innov17 Llc ROR modulators and their uses
KR20150135359A (ko) * 2013-03-14 2015-12-02 컨버진 엘엘씨 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
US9199988B2 (en) 2013-03-27 2015-12-01 Boehringer Ingelheim International Gmbh Dihydroquinazolinone analogues

Also Published As

Publication number Publication date
BR112016015311B1 (pt) 2023-01-24
ES2687497T3 (es) 2018-10-25
KR102394518B1 (ko) 2022-05-06
EA029224B1 (ru) 2018-02-28
PT3092227T (pt) 2018-10-24
MY190835A (en) 2022-05-12
PE20161021A1 (es) 2016-11-09
US10077259B2 (en) 2018-09-18
CN106061966B (zh) 2018-12-07
RS57586B1 (sr) 2018-11-30
BR112016015311A2 (es) 2017-08-08
CA2934788C (en) 2021-12-07
US20160368906A1 (en) 2016-12-22
PH12016501355B1 (en) 2017-02-06
LT3092227T (lt) 2018-08-10
SI3092227T1 (sl) 2018-10-30
US10590118B2 (en) 2020-03-17
CL2016001737A1 (es) 2017-02-03
US20180339982A1 (en) 2018-11-29
IL246140A0 (en) 2016-08-02
PH12016501355A1 (en) 2017-02-06
MA39172B1 (fr) 2018-10-31
WO2015104653A1 (en) 2015-07-16
CN106061966A (zh) 2016-10-26
SA516371448B1 (ar) 2018-10-15
HUE041546T2 (hu) 2019-05-28
MA39172A1 (fr) 2018-04-30
EA201691404A1 (ru) 2016-10-31
NZ721993A (en) 2021-05-28
PL3092227T3 (pl) 2018-12-31
CY1122046T1 (el) 2020-07-31
JP2017502057A (ja) 2017-01-19
UA117165C2 (uk) 2018-06-25
SG11201604916YA (en) 2016-07-28
JP6480944B2 (ja) 2019-03-13
AU2015205339B2 (en) 2018-07-05
KR20160106164A (ko) 2016-09-09
DK3092227T3 (en) 2018-09-03
HRP20181650T1 (hr) 2018-12-14
EP3092227A1 (en) 2016-11-16
AU2015205339A1 (en) 2016-07-07
IL246140B (en) 2019-09-26
EP3092227B1 (en) 2018-07-11
CA2934788A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
PH12018501920A1 (en) Bromodomain inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MY190429A (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016007440A (es) Inhibidores del bromodominio.
TW201613864A (en) Novel compounds
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
TN2017000384A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека